| Small-Caps Post Third Strongest Start to Year |
| |
|
The small-cap Russell 2000 index has rallied 16.5% in 2019, the third best start to a year since the index's inception.
"Can't draw up a better start to new year than this, however we need a pullback," Steven DeSanctis, a Jefferies strategist, said in a note on Sunday. "We'd like the market to take a breather."
Growth stocks are seen beating value stocks in the small-cap world given the earnings growth, according to DeSanctis.
|
|
| |
|
| GSRX Industries (OTCQB: GSRX) Opens Its First CBD Retail Store |
| |
|
GSRX Industries (OTCQB: GSRX) opened its first brick-and-mortar Pure and Natural retail kiosk at Governor's Square Mall, just north of Nashville in Clarksville, TN.
Why It Matters: Pure and Natural retail kiosks are the brick-and-mortar extensions of the Company's eCommerce platform GetPureAndNatural.com, and feature the Company's own brand of pure, full-spectrum Hemp-based non-THC CBD products that are naturally certified organic. Each Pure and Natural location will carry a broad range of pharmaceutical grade CBD products, including health, wellness, skin care and pet products.
Key Quote: “We are pleased with early sales at our first Pure and Natural kiosk, especially as we are already identifying and securing additional locations.” – Les Ball, CEO
Additional Information: GSRX will host an exclusive investor webinar this Thursday, February 21, at 11 am EST. To attend, please go to https://www.redchip.com/events/38/GSRX-Industries-Webinar.
Disclosure
GSRX Industries (OTCQB: GSRX) is a client of RedChip Companies. RedChip Companies, Inc. received 1,000,000 registered shares of GSRX for consulting services. Be advised RedChip intends to sell some or all of its shares at any time, including when you are buying.
|
|
| |
|
| Level Brands (NYSE American: LEVB) Announces Significant Sales Growth at Its cbdMD Subsidiary |
| |
|
Level Brands (NYSE American: LEVB) announced results for its quarter ended December 31, 2018 last week. While net sales were up and net loss reduced, the real story was the significant sequential sales growth of its recently acquired subsidiary, cbdMD.
Why It Matters: Since commencing sales in January 2018, cbdMD has generated approximately $7.5 million in total net sales for calendar 2018. Sales increased sequentially throughout calendar 2018, with net sales of $580,000, $1,618,000, $1,696,000 and $3,625,000, for the quarters ending March 31, 2018, June 30, 2018, September 30, 2018 and December 31, 2018, respectively (with October, November and December 2018 unaudited net sales of approximately $1,074,000, $1,166,000, and $1,384,000, respectively). This growth has continued into January at a pace commensurate with achievement of the company’s year one earnout target of $20 million.
Key Quote: “Moving forward, the passage of the Farm Bill opens up the opportunity to expand distribution to larger wholesalers and retailers, which we plan to pursue vigorously in 2019 and beyond. R&D efforts are also ongoing as we seek to identify and develop new CBD product offerings to meet evolving consumer demands.” – Martin Sumichrast, Chairman and CEO
What’s Next: With strong growth of its CBD business underway, Level Brands is going all in. Following its positive earnings announcement last week, the company announced it plans to change its name to cbdMD. Shareholders will get to vote on this and other issues at the upcoming annual meeting in March.
Disclosure
Level Brands (NYSE American: LEVB) is a client of RedChip Companies. LEVB agreed to pay RedChip a monthly cash fee and 5,000 shares of Rule 144 stock for four months of RedChip investor awareness services.
|
|
| |
|
| eMARINE Global (OTC: EMRN) Earns Support of Key Government Officials |
| |
|
eMARINE Global (OTC: EMRN), a leading provider of information and communications technology (ICT) for the maritime industry, was recognized as a leading solution provider and for its contributions to the local economy in Ulsan during a recent visit by the Deputy Minister of Science and ICT to the Company's Ulsan R&D center. The Deputy Minister was accompanied by the heads of Ulsan and national ICT promotions, as well as Ulsan city officials.
Why It Matters: EMRN demonstrated its smart-ship and autonomous-ship solutions during the delegates' visit, including its voyage optimization, collision avoidance, engine status monitoring, remote maintenance, and other IoT-based solutions. The deputy minister and accompanying officers, whose organizations are responsible for promoting Korean technology companies and the Fourth Industrial Revolution, were impressed by the company’s technology edge as well as the work it has done and continues to do with the Korean Coast Guard, the Korean Navy, Hyundai Global Services, and others, offering support for commercialization and marketing, domestically and abroad.
Key Quote: “On behalf of Korean government, the deputy minister assured their support in commercialization and marketing, locally as well as globally.” – Ung Gyu Kim, Chairman and CEO
Disclosure
eMARINE Global (OTC: EMRN) is a client of RedChip Companies. RedChip Companies, Inc. owns 613,000 shares of EMRN common stock.
|
|
| |
|
| Nemaura Medical (NASDAQ: NMRD) Reports Third Quarter Results |
| |
|
Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, reported its results last week for the third quarter ended December 31, 2018.
Why It Matters: NMRD reported cash of $5 million at quarter end, in part due to a successful capital raise earlier in the period. Other notable achievements during the quarter include improvements to the underlying technology, granting of its US Patent, and the completion of key stages of the technical file review for CE Mark approval.
Key Quote: “Over the past quarter, we have bolstered our financial position to better support the upcoming commercial launch of SugarBEAT® and filing of our FDA 510(k) submission.” – Dr. Faz Chowdhury, CEO
Disclosure
Nemaura Medical (NASDAQ: NMRD) is a client of RedChip Companies. NMRD agreed to pay RedChip a monthly cash fee for investor awareness services.
|
|
| |
|
| Cemtrex (NASDAQ: CETX) Announces Johns Hopkins University as Latest SmartDesk Customer |
| |
|
Cemtrex Inc. (NASDAQ: CETX), a leading global technology company, announced that Johns Hopkins University is Cemtrex’s latest SmartDesk Enterprise Client to evaluate the product for widescale use on its campus.
The University is first exploring use of SmartDesks within their massive Applied Physics Laboratory, a leading laboratory that advises major government agencies like NASA on technology.
Key Quote: “Johns Hopkins represents another major client for the SmartDesk,” said Saagar Govil, CEO and Chairman of Cemtrex, Inc.
The Backstory: Cemtrex is a diversified technology company driving innovation in a wide range of sectors, including smart technology, virtual and augmented realities, advanced electronic systems, industrial solutions, and intelligent security systems. Cemtrex is the manufacturer of the SmartDesk, the world’s most advanced workstation. Find us on the web at www.cemtrex.com.
Disclosure
Cemtrex, Inc. (NASDAQ: CETX) agreed to pay RedChip Companies, Inc. a monthly cash fee for three (3) months of investor relation awareness services.
|
|
| |
|
| Interpace Diagnostics (NASDAQ: IDXG) Announces First Independent Publication Demonstrating Clinical Utility of BarreGEN® |
| |
|
Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced that BMJ Open Gastroenterology, an on-line, peer-reviewed, open access gastroenterology journal dedicated to publishing high-quality medical research from all disciplines and therapeutic areas of gastroenterology, has provided the first independent evidence that BarreGEN®, the Company’s lead pipeline product, performed effectively as a biomarker tool for predicting risk of developing more advanced stages of disease prior to the visible appearance of advanced histology. This is the first publication resulting from work related to the Company’s ongoing Clinical Experience Program (CEP) under which several sites across the country are using BarreGEN to provide input on its clinical utility in a real-world setting.
Key Quote: “We are pleased that such a prestigious institution has published this peer-reviewed study providing the first independent evidence of the clinical utility of BarreGEN in identifying those patients who are likely to progress from Barrett’s Esophagus to more advanced stages of the disease associated with cancer”. Jack Stover, President and CEO of Interpace
The Backstory: Interpace is a fully integrated commercial and bioinformatics company that provides clinically useful molecular and related first line diagnostic tests and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. The Company currently has four commercialized molecular tests and one test in a clinical evaluation process (CEP); PancraGEN® for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGeNEXT® for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay.
|
|
| |
|
| Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) Announces Phase 2 Study with Company’s Lead Drug Trans-sodium Crocetinate (TSC) for Treatment of Acute Stroke |
| |
|
Diffusion Pharmaceuticals Inc (NASDAQ: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it’s needed most, today announced the presentation of a poster detailing an innovative on-ambulance Phase 2 study with the Company’s lead drug trans sodium crocetinate (TSC) for the treatment of acute stroke.
Key Quote: “We are very pleased to highlight the details of this innovative trial design at such a prestigious medical conference,” said David Kalergis, Chairman and CEO of Diffusion.
The Backstory: Diffusion Pharmaceuticals Inc. is an innovative biotechnology company developing new treatments that improve the body’s ability to bring oxygen to the areas where it’s needed most, offering new hope for the treatment of life-threatening medical conditions.
Diffusion’s lead drug, trans sodium crocetinate (TSC), was originally developed in conjunction with the Office of Naval Research, which was seeking a way to treat hemorrhagic shock caused by massive blood loss on the battlefield.
|
|
| |
|
| |
| Quote of the Week |
| |
"Invest in something you can get your arms around and be very conservative, own enough stock so that you are not putting all your eggs in one basket."
- Dave Maley, Manager Ariel Discovery Fund |
|
|
|
|
|
|
|
| About RedChip |
| |
| RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on small-cap and mid-cap companies. Since 1992, RedChip has delivered concrete, measurable results for its clients through the most comprehensive service platform in the industry for small-cap and mid-cap companies. These services include a worldwide distribution network for its stock research written by analysts holding the CFA designation; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated over 2.3 million unique investor views; quarterly global online institutional and retail investor conferences that reach over 10,000 investors annually; "The RedChip Money Report" television show which airs in 100 million homes across the U.S. on The Family Channel; a weekly newsletter delivered to 60,000 investors; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. |
| |
| RedChip Disclosure |
| |
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that the RedChip Companies Inc. is an investor relations firm hired by certain Companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and view RedChip’s Disclosures. |
|
| |
|
|
| |
|
|
Copyright © 2019 RedChip Companies, Inc. All Rights Reserved.
You are receiving this message because this email address has signed up to receive News Alerts.
|
|
|
|
|
|
